By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the...

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part...

Download the Complete Report Here Aurora Cannabis Inc. (ACB) Y26 Beat Underscores Medical Cannabis Momentum; FY27 Reset Reflects Canadian Reimbursement Cut, but Long-Term Growth Remains on Track. Key Takeaways: FY26 topped management’s outlook, with net revenue up 11% to C$320.6...

Aurora Cannabis Inc. (ACB) Y26 Beat Underscores Medical Cannabis Momentum; FY27 Reset Reflects Canadian Reimbursement Cut, but Long-Term Growth Remains on Track. Read Exec Edge’s Initiation on ACB Here Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com...

By Karen Roman Enhanced Group Inc. (NYSE: ENHA) said it closed a $50 million private investment in public equity financing. The transaction was led by Apeiron Investment Group, Enhanced co-founder and Chairman’s Christian Angermayer family office, as well as co-Founder...

Suja Life, Inc. (Nasdaq: SUJA) debuted last month, offering investors exposure to the leading platform for natural healthy beverages Vertically-integrated model produces drinks from farm to bottle in as few as 8 days, with almost all produced and sourced in...

By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Association 2026 Congress taking place on June 11-14, 2026, in Stockholm, Sweden. The global TENACITY-01 study...

By Karen Roman Suja Life, Inc. (Nasdaq: SUJA) said first quarter net sales grew 22.5% to $107.1 million compared to $87.4 million the year prior, while gross profit increased 24.3% to $54.1 million, or 50.5% of net sales, compared to...

By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b of this clinical trial will study CTA313 in patients with systemic...